Development of gatifloxacin-loaded cationic polymeric nanoparticles for ocular drug delivery

References

• Solomon R, Donnenfeld ED, Perry HD, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 2005;112:466–469.
   PubMed Web of Science ®Google Scholar
• Fung-Tomc J, Minassian B, Kolek B, et al. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother 2000;45:437–446.
   PubMed Web of Science ®Google Scholar
• Kaliamurthy J, Nelson CA, Geraldine P, et al. Comparison of in vitro susceptibilities of ocular bacterial isolates to gatifloxacin and other topical antibiotics. Ophthalmic Res 2005;37:117–122.
   PubMed Web of Science ®Google Scholar
• Schultz C. Gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis: safety, efficacy and patient perspective. Ophthalmol Eye Dis 2012;4:65.
   PubMedGoogle Scholar
• Pawar P, Katara R, Mishra S, Majumdar DK. Topical ocular delivery of fluoroquinolones. Expert Opin Drug Deliv 2013;10:691–711.
   PubMed Web of Science ®Google Scholar
• Al-Abdullah ES. Gatifloxacin. Profiles of drug substances, excipients and related methodology. Milford, NJ: Academic Press; 2012:183–243.
   Google Scholar
• Sultana Y, Jain R, Aqil M, Ali A. Review of ocular drug delivery. Curr Drug Deliv 2006;3:207–217.
   PubMedGoogle Scholar
• Patel HA, Patel JK, Patel KN, Patel RR. Ophthalmic drug delivery system – a review. Der Pharmacia Lett 2010;2:100–115.
   Google Scholar
• Dillen K, Vandervoort J, Van den Mooter G, Ludwig A. Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. Int J Pharm 2006;314:72–82.
   PubMed Web of Science ®Google Scholar
• Bu HZ, Gukasyan HJ, Goulet L, et al. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr Drug Metab 2007;8:91–107.
   PubMed Web of Science ®Google Scholar
• Del Pozo-Rodríguez A, Delgado D, Gascón AR, Solinís MA. Lipid nanoparticles as drug/gene delivery systems to the retina. J Ocul Pharmacol Ther 2013;29:173–188.
   PubMed Web of Science ®Google Scholar
• Rajendran N, Natrajan R, Kumar R, Selvaraj S. Acyclovir-loaded chitosan nanoparticles for ocular delivery. Asian J Pharm 2010;4:220.
   Google Scholar
• Sezer AD, Cevher E. Topical drug delivery using chitosan nano-and microparticles. Expert Opin Drug Deliv 2012;9:1129–1146.
   PubMed Web of Science ®Google Scholar
• Motwani SK, Chopra S, Talegaonkar S, et al. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 2008;68:513–525.
   PubMed Web of Science ®Google Scholar
• Rong X, Xie Y, Hao X, et al. Applications of polymeric nanocapsules in field of drug delivery systems. Curr Drug Discov Technol 2011;8:173–187.
   PubMedGoogle Scholar
• Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 2009;26:1025–1058.
   PubMed Web of Science ®Google Scholar
• Lee EJ, Khan SA, Park JK, Lim KH. Studies on the characteristics of drug-loaded gelatin nanoparticles prepared by nanoprecipitation. Bioprocess Biosyst Eng 2012;35:297–307.
   PubMed Web of Science ®Google Scholar
• Devarajan PV, Sonavane GS. Preparation and in vitro/in vivo evaluation of gliclazide loaded Eudragit nanoparticles as a sustained release carriers. Drug Dev Ind Pharm 2007;33:101–111.
   PubMed Web of Science ®Google Scholar
• Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Diclofenac-loaded Eudragit S100 nanosuspension for ophthalmic delivery. J Microencapsul 2011;28:37–45.
   PubMed Web of Science ®Google Scholar
• Das S, Suresh PK, Desmukh R. Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery. Nanomedicine 2010;6:318–323.
   PubMed Web of Science ®Google Scholar
• Ibrahim HK, El-Leithy IS, Makky AA. Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. Mol Pharm 2010;7:576–585.
   PubMed Web of Science ®Google Scholar
• Loveymi BD, Jelvehgari M, Zakeri-Milani P, Valizadeh H. Design of vancomycin RS-100 nanoparticles in order to increase the intestinal permeability. Adv Pharm Bull 2012;2:43–56.
   PubMedGoogle Scholar
• Jiang B, Hu L, Gao C, Shen J. Ibuprofen-loaded nanoparticles prepared by a co-precipitation method and their release properties. Int J Pharm 2005;304:220–230.
   PubMed Web of Science ®Google Scholar
• Pignatello R, Bucolo C, Ferrara P, et al. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 2002;16:53–61.
   PubMed Web of Science ®Google Scholar
• Ceulemans J, Ludwig A. Optimisation of carbomer viscous eye drops: an in vitro experimental design approach using rheological techniques. Eur J Pharm Biopharm 2002;54:41–50.
   PubMed Web of Science ®Google Scholar
• Herrera LC, Tesoriero MVD, Hermida LG, et al. In vitro release testing of PLGA microspheres with Franz diffusion cells. Vitro 2012;19:6–11.
   Google Scholar
• Ghosh B, Ramamoorthy D. Effects of Silver nanoparticles on Escherichia coli and it's implications. Int J Chem Sci 2010;8:31–40.
   Google Scholar
• Lkhagvajav N, Yasa I, Celik E, et al. Antimicrobial activity of colloidal silver nanoparticles prepared by sol–gel method. Digest J Nanomater Biostruct 2011;6:149–154.
   Web of Science ®Google Scholar
• Leroux J, Allémann E, De Jaeghere F, et al. Biodegradable nanoparticles – from sustained release formulations to improved site specific drug delivery. J Control Release 1996;39:339–350.
   Web of Science ®Google Scholar
• Guhagarkar SA, Malshe VC, Devarajan PV. Nanoparticles of polyethylene sebacate: a new biodegradable polymer. AAPS PharmSciTech 2009;10:935–942.
   PubMed Web of Science ®Google Scholar
• Katara R, Majumdar DK. Eudragit RL 100-based nanoparticulate system of aceclofenac for ocular delivery. Colloids Surf B Biointerfaces 2013;103:455–462.
   PubMed Web of Science ®Google Scholar
• Pignatello R, Bucolo C, Spedalieri G, et al. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 2002;23:3247–3255.
   PubMed Web of Science ®Google Scholar
• Rabinovich-Guilatt L, Couvreur P, Lambert G, Dubernet C. Cationic vectors in ocular drug delivery. J Drug Target 2004;12:623–633.
   PubMed Web of Science ®Google Scholar
• De Campos AM, Sánchez A, Gref R, et al. The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sci 2003;20:73–81.
   PubMed Web of Science ®Google Scholar
• Instruments M. Zeta potential: an introduction in 30 minutes. Zetasizer Nano Serles Technical Note. MRK654-01 2011.
   Google Scholar
• Bhagav P, Upadhyay H, Chandran S. Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation. AAPS PharmSciTech 2011;12:1087–1101.
   PubMed Web of Science ®Google Scholar
• McCarron P, Woolfson AD, Keating SM. Sustained release of 5-fluorouracil from polymeric nanoparticles. J Pharm Pharmacol 2000;52:1451–1459.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Bodmeier R. Incorporation of polymeric nanoparticles into solid dosage forms. J Control Release 1999;57:115–125.
   PubMed Web of Science ®Google Scholar
• Bräuer L, Johl M, Börgermann J, et al. Detection and localization of the hydrophobic surfactant proteins B and C in human tear fluid and the human lacrimal system. Curr Eye Res 2007;32:931–938.
   PubMed Web of Science ®Google Scholar
• Bräuer L, Paulsen FP. Tear film and ocular surface surfactants. J Epithel Biol Pharmacol 2008;1:62–67.
   Google Scholar
• Duchêne D, Ponchel G, Wouessidjewe D. Cyclodextrins in targeting. Application to nanoparticles. Adv Drug Deliv Rev 1999;36:29–40.
   PubMed Web of Science ®Google Scholar
• Bibby DC, Davies NM, Tucker IG. Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. Int J Pharm 2000;197:1–11.
   PubMed Web of Science ®Google Scholar
• Ayaki M, Iwasawa A, Soda M, et al. Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines. Clin Ophthalmol 2010;4:1019–1024.
   PubMedGoogle Scholar
• Thompson AM. Ocular toxicity of fluoroquinolones. Clin Exp Ophthalmol 2007;35:566–577.
   PubMed Web of Science ®Google Scholar
• Fish DN, North DS. Gatifloxacin, an advanced 8-methoxy fluoroquinolone. Pharmacotherapy: J Human Pharmacol Drug Therapy 2001;21:35–59.
   Web of Science ®Google Scholar
• Boyd LB, Maynard MJ, Morgan-Linnell SK, et al. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates. Antimicrob Agents Chemother 2009;53:229–234.
   PubMed Web of Science ®Google Scholar